Prognostic and Predictive Biomarkers in Patients With Coronavirus Disease 2019 Treated With Tocilizumab in a Randomized Controlled Trial*Jennifer Tom, Fang Cai, Min Bao et al.|Critical Care Medicine|2021Cited by 42
2022 White Paper on Recent Issues in Bioanalysis: Fda Draft Guidance on Immunogenicity Information in Prescription Drug Labeling, Lnp & Viral Vectors Therapeutics/Vaccines Immunogenicity, Prolongation Effect, Ada Affinity, Risk-Based Approaches, Ngs, Qpcr, Ddpcr Assays ( <u>Part 3</u> – Recommendations on Gene Therapy, Cell Therapy, Vaccines Immunogenicity & Technologies; Immunogenicity & Risk Assessment of Biotherapeutics and Novel Modalities; NAb Assays Integrated Approach)Luying Pan, Swati Gupta, David Bettoun et al.|Bioanalysis|2023Cited by 15
Prognostic and predictive biomarkers in patients with COVID-19 treated with tocilizumab in a randomised controlled trialJennifer Tom, Fang Cai, Min Bao et al.|medRxiv|2020Cited by 5